GSK 366

Overview

GSK 366 is a type II kynurenine-3-monooxygenase ( KMO ) inhibitor with IC 50 values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens -KMO (Pf-KMO). GSK 366 binds to KMO’s substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H 2 O 2 ) production and reduces H 2 O 2 levels. GSK 366 can be used for the researches of inflammation and neurological disease , such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimer’s disease.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > KMO

Product Information

• Catalog No.: HY-119171
• CAS No.: 1953157-39-5
• Molecular Formula: C17H16ClN3O4
• Molecular Weight: 361.78
• Purity: 98.17%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (5.75 mM); Clear solution
• Availability: In-stock

Source

Original product source